JP Morgan analyst Chris Schott reiterated an Overweight rating on Zoetis but reduced the price target from $130 to $115. This indicates a slightly less optimistic outlook on the stock's near-term valuation, though the overall positive sentiment remains.
JP Morgan analyst Chris Schott maintained an 'Overweight' rating on Zoetis, signaling continued confidence in the company's long-term prospects. However, the price target was lowered from $130 to $115, suggesting a recalibration of near-term valuation expectations. This move could lead to some short-term downward pressure on ZTS stock as investors digest the reduced price target, despite the maintained positive rating. For traders, this presents a potential opportunity to buy on a dip if they believe the 'Overweight' rating holds more weight than the price target adjustment, or a risk if the price target cut signals deeper underlying concerns not fully articulated.